Anna Ossami Saidy

4PUBLICATIONS

39CO-AUTHORS

Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classified

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|Jun 19, 2026

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

|Aug 20, 2025

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Markus Maulhardt, Simon Call, Hristo Boyadzhiev

|May 22, 2025

Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition.

Anna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont

|Feb 06, 2025

Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma.

Nora Liebers, Ariane Boumendil, Hervé Finel

Pageof 1

Frequent Collaborators

Philipp Berning

Anna Sureda

Ali Bazarbachi

Carlos Solano

Peter Dreger

Nicolaus Kröger

Ariane Boumendil

Wolfgang Bethge

Ben-Niklas Baermann

Yasmina Serroukh

Frequent Collaborators

Philipp Berning

Anna Sureda

Ali Bazarbachi

Carlos Solano